Introduction
Clinical design in pediatric rare disease research often requires complicated end point models with multiple clinical outcome assessments (COAs) to capture the constructs. This commentary will focus on the use of existing standardized instruments that consider development by age and classify function relative to normative values. In this discussion, hypophosphatasia (HPP) is used to illustrate COA selection in a pediatric rare disease. HPP, a genetic metabolic musculoskeletal disorder, is caused by mutations in the tissue-nonspecific alkaline phosphatase gene [1] . Heterogeneous manifestations can include rickets, fractures, muscle weakness, limb deformities, pain, and respiratory compromise, which result in delayed acquisition of age-appropriate developmental skills, gait impairments, and decreased functional independence in activities of daily living (ADL) [1] . The disease has a particularly high burden in children and is associated with high mortality rates in infants [2] .
Use of Existing Standardized Developmental Assessments
Rare disease studies often have a small sample size that is insufficient to divide by group-level differences in age and function. Normative data can define function in a heterogeneous sample and be used to characterize the disease presentation in the natural history and treatment groups. Rare diseases often present with multisystem impairments that limit ability to capture the direct impact of disease-defining concepts. Comprehensive developmental COAs can be used to characterize the disease impact on age-appropriate markers across multiple domains, examine the relationship between domains, and guide selection or development of additional disease-specific measures.
Pediatric rare disease clinical trials often enroll a wide age distribution. Gross and fine motor skills, communication, cognition, and independence in ADL vary by age, and it may be difficult to distinguish between treatment effects and change due to developmental maturation. Identical function may be age-appropriate for a younger child and considered atypical or delayed in an older child. Variability in typical function by age requires that multiple age versions be developed for disease-specific validated patient-reported outcomes. Comparisons with a normative sample in an existing tool can provide age-appropriate developmental expectations.
Existing standardized developmental assessments can provide a range of values to measure treatment benefits including, but not limited to, standard scores (including scale scores), percentile rank, age-equivalent (AE) scores, and developmental quotients (DQs) [3] . Different values may be used to interpret treatment benefit in infantile and juvenile disease phenotypes. The infantile form of the rare disease may include progressive loss of developmental skills and high mortality, and treatment benefit may be defined by the acquisition of a developmental skill that exceeds function observed in the natural history study. The rate of skill acquisition in response to a treatment may be slower than in the normative sample and improvement may be reflected only as an increase in AE scores. Standard scores can be insensitive to change in low-functioning children because either the children fall below the test floor or the rate of change is slower than in typically developing children in the normative sample, and standard scores either plateau or decline [3] . In a progressive condition in which treatment is focused on arresting deterioration, a treatment response may be indicated only by stable AE values because a subsequent decline in standard scores will result with increased age. DQ (AE/chronological age × 100) can be sensitive to age as a determinant of disease progression in children with low function and can be used to compare the rate of change between disease natural history and intervention groups [3] . 
Application to HPP

Bayley Scales of Infant and Toddler Development-Third Edition
The five developmental domains of the Bayley Scales of Infant and Toddler Development-Third Edition (Bayley-III) (i.e., cognition, language, motor skills, social-emotional behavior, and adaptive behavior) were developed (normed and validated) for use in impaired and healthy children aged between 1 and 42 months [4] . The Bayley-III is regarded as the best practice tool, and is thus most widely used in clinical practice [5] . In an openlabel, retrospective study, 11 patients were assessed using Bayley-III at baseline and at 24 and 48 weeks after initiation of asfotase alfa for treatment of HPP [1, 2] . All patients had fine motor, gross motor, and cognitive delays at baseline, and 87.5% of patients for whom data were available showed improvements in Fig. 1 
Potential strategies
• Use comprehensive prospective, observational, natural history studies with multiple COAs to gain insight into the multisystem impacts on age-appropriate markers (symptoms/impacts)
• Use these natural history studies to gain insights into the COA performance (sensitivity and specificity) and to look into the relationships between outcome measures (consider language, motor ability, and behavioral and cultural aspects)
• Characterize disease by distinct age and functional groups using natural history data, KOLs, patient and caregiver perspectives
• Treatment benefit in the infant population may be defined by global development and the pediatric/ juvenile group may require performance-based or patient-reported assessments that are focused on a specific functional skill that is age-specific or disease-specific
• Treatment benefit may be defined by a responder definition on the basis of acquiring a developmental skill that exceeds function observed in the natural history study
• Treatment benefit may also be defined by DQs (ageequivalent scores/chronological age × 100) and compared with decline in DQ in the natural history study [22] • Use KOL, focus group, caregiver, and patient perspectives to define treatment benefit 
these areas [1] . AE scores were used to illustrate linear skill acquisition, and scaled scores (mean 10 ± 3) illustrated rate and level of skill acquisition relative to a normative sample, with median (minimum, maximum) gross motor scaled scores increasing from 1 (1, 8) at baseline to 2 (1, 5) at week 48 [6] .
Bruininks-Oseretsky Test of Motor Proficiency-Second Edition
The purpose of the Bruininks-Oseretsky Test of Motor Proficiency-Second Edition (BOT-2) is to assess motor skills, including differentiated measures of gross motor and fine motor proficiency, in individuals aged 4 to 21 years [7] . BOT-2 is a standardized sex-specific, norm-referenced, discriminative, and evaluative tool [7, 8] . All items are administered to the entire age range and point scores are calculated from the raw scores for each item. Scaled scores and AE scores can be calculated from combined point scores for each subtest, and scaled scores can be combined to derive composite standard scores and percentile ranks [7] . It would not be appropriate to calculate mean point scores across a clinical trial with a wide age distribution because all the items within a subtest are administered to patients of all ages. Instead, scaled scores should be used because they are based on age-specific normative data [7, 9] . For example, a running speed and agility point score of 35 for a 10-year-old child would equate to a scaled score of 15 (normative mean), and the same point score for a 17-year-old adolescent would equate to a scaled score of 10, which is 1 SD less than the normative mean for that age category.
In a phase II, open-label study of asfotase alfa in children aged 5 to 12 years (N ¼ 13) with HPP, only the running speed and agility subtest and the strength subtest of BOT-2 were used because they were the most relevant to the disease-specific impairments and mobility restrictions and involved a reasonable amount of administrative time when paired with additional outcomes. At baseline, the median scaled score for both these BOT-2 subtests were more than 2 SDs below the normative mean. Asfotase alfa treatment resulted in significant and clinically meaningful improvements in strength (P o 0.0003) and running speed and agility (P o 0.0001), demonstrated by improvements in BOT-2 mean scores to ±1 SD of normal at last assessment (week 144 or 168). The treatment had a proximal impact on the strength subtest, with values within the normal range by month 6, and a more distal impact on the running speed and agility subtest, with improvements evident at month 6 but not within the normal range until year 3.
Childhood Health Assessment Questionnaire and Pediatric Outcomes Data Collection Instrument
The Childhood Health Assessment Questionnaire (CHAQ) is a functional health status questionnaire for children aged between 6 months and 18 years, which measures how the illness and pain affects ADL [10] [11] [12] . A disability index from 0 to 3 (no disability to maximum disability) is calculated as well as a discomfort visual analogue scale.
The Pediatric Outcomes Data Collection Instrument (PODCI) is designed to assess overall health, pain, and ability to participate in both ADL and more vigorous activities in children and adolescents [13] . Questionnaires include items that are either self-reported and/or reported by the parent/caregiver, with raw scores converted to a standardized scale from 0 to 100, and higher scores corresponding to less disability [13] . Normative scores can also be calculated on the basis of a mean of 50 and an SD of 10.
In a phase II, open-label study of 5-to 12-year-old children (N ¼ 13) with HPP receiving asfotase alfa, physical function, ADL, and pain were assessed using CHAQ and PODCI [14] . At baseline, children had difficulty with upper extremity tasks, functional mobility items, and participation in community recreation and sports [14] . Decreases in disability and pain were consistent across both measures. Median parent-reported normative PODCI scores for global function, sports/physical function, and transfer/ basic mobility all improved and reached normal values at 6 months (P o 0.05). The median (minimum, maximum) CHAQ disability score decreased from 
Handheld Dynamometry
Handheld dynamometry (HHD) is a reliable and easy-to-use method to measure muscle strength [15] . In children and adolescents, torque can be calculated and compared with sex-specific norms [15, 16] . In 5-to 12-year-old children with HPP, bilateral hip and knee extension and flexion, hip abduction, and grip strength were assessed by HHD [17] . Baseline strength ranged from median 32% (9.4, 52.7) predicted in the hip extensor to 60% (20.8, 149 .2) predicted for grip (reported in torque for the right side as percent predicted for age-and weight-matched healthy peers). With asfotase alfa treatment, strength in all tested muscle groups, except grip, improved and continued to improve until the last assessment (P o 0.05); a median of 83% (45.7, 118.7) of predicted value was achieved for hip abductor at the last assessment (week 144 or 168) [17] .
6-Minute Walk Test
The 6-minute walk test (6MWT) is a validated tool used to assess the distance a patient can walk on a level course in 6 minutes. Normative data are available for children and the distance walked can be compared as a percent of the predicted values by age, sex, and weight. The 6MWT reflects an integrated exercise response of multiple systems including the cardiorespiratory, neurological, and musculoskeletal systems and does not isolate the specific system of change. In 5-to 12-year-old children with HPP, a rapid improvement in 6MWT scores was demonstrated with asfotase alfa treatment: the median score increased from 61% predicted at baseline to within the normal range (80%-100% of predicted) after 3 months of treatment, and remained within the normal range through 5 years of treatment [18] .
Modified Performance-Oriented Mobility Assessment-Gait Characteristics
The Performance-Oriented Mobility Assessment-Gait was modified (MPOMA-G) to provide improved sensitivity for HPP-related impairments and to target gait as a disease-specific area of anticipated treatment benefit [19] . The modification process included validation with HPP key opinion leaders, evaluation of the relationship between the MPOMA-G scores and other clinical data points, and measurement of inter-rater reliability from archived gait videos in a natural history database. In a substudy of a larger retrospective, noninterventional natural history study, all six children with HPP had clinically significant gait impairments that persisted, as assessed from gait videos using MPOMA-G [20] . In another study, all 14 children with HPP had gait impairments at baseline, and 8 patients treated with asfotase alfa showed significantly greater improvements compared with controls at the last assessment [21] .
Conclusions
Pediatric rare diseases present unique challenges in clinical trial design and in selection of COAs that can be used to support claims in medical product labeling. Guidance is not available on best practices that deal with developing children, in whom cognition, motor skills, language, and level of independence in ADL vary greatly by age. In this example, multiple end points were required to capture multisystem impacts and to tell the complicated story from biochemical parameters to age-appropriate recreational and community participation. The measurement strategy that was used in HPP is optimal when the treatmentrelated improvements in symptoms and function are expected. When attenuation of disease progression is the treatment benefit or function is expected at a slower rate of skill acquisition than the typical population, AE scores or DQs should be considered.
Similar to HPP, many rare diseases present with multisystem impairments and a wide distribution of age and functional levels that are desirable to be included within labeling claims for medical product approval. It is imperative to consider multiple COAs early in the development process to design comprehensive prospective, observational, and natural history studies to gain insight into the multisystem impacts on age-appropriate markers. The HPP studies paired performance-and clinicianrated assessments to capture a quantitative measure of development and important caregiver perspective of the disease impact in the home community and school environment. The COAs that were highlighted for HPP are not necessarily specific to rare diseases. They are commonly administered in developmental evaluation and intervention clinics and reflect current standards for childhood assessment. COAs that provide normative data can help support market and payer approval and reimbursement for the approved drug intervention.
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